Capstone Investment Advisors LLC Takes $1.04 Million Position in Immunome, Inc. (NASDAQ:IMNM)

Capstone Investment Advisors LLC bought a new stake in Immunome, Inc. (NASDAQ:IMNM) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 42,300 shares of the company’s stock, valued at approximately $1,044,000. Capstone Investment Advisors LLC owned approximately 0.07% of Immunome at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Avidity Partners Management LP acquired a new position in shares of Immunome in the fourth quarter valued at $14,268,000. Cerity Partners LLC acquired a new position in Immunome during the fourth quarter worth $656,000. Mayo Clinic acquired a new position in Immunome during the fourth quarter worth $1,161,000. Emfo LLC acquired a new position in Immunome during the fourth quarter worth $633,000. Finally, Jump Financial LLC acquired a new position in Immunome during the fourth quarter worth $172,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Immunome Trading Down 0.7 %

Immunome stock traded down $0.09 during mid-day trading on Friday, hitting $12.03. The stock had a trading volume of 517,450 shares, compared to its average volume of 1,310,077. The stock has a 50-day simple moving average of $14.11 and a two-hundred day simple moving average of $17.16. The stock has a market capitalization of $721.43 million, a PE ratio of -1.59 and a beta of 1.79. Immunome, Inc. has a 12 month low of $6.13 and a 12 month high of $30.96.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.46. Immunome had a negative return on equity of 37.33% and a negative net margin of 1,829.44%. The business had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $4.00 million. Sell-side analysts expect that Immunome, Inc. will post -1.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Jean Jacques Bienaime bought 2,000 shares of Immunome stock in a transaction on Tuesday, May 21st. The shares were purchased at an average price of $13.57 per share, for a total transaction of $27,140.00. Following the completion of the acquisition, the director now owns 9,615 shares in the company, valued at $130,475.55. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 8.60% of the company’s stock.

Wall Street Analysts Forecast Growth

IMNM has been the subject of several recent analyst reports. Guggenheim initiated coverage on Immunome in a research note on Monday, April 15th. They set a “buy” rating and a $35.00 price objective for the company. Wedbush restated an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Tuesday, May 14th. JPMorgan Chase & Co. initiated coverage on Immunome in a research note on Tuesday, April 30th. They issued an “overweight” rating and a $24.00 target price for the company. Finally, Piper Sandler initiated coverage on Immunome in a research note on Friday, May 31st. They issued an “overweight” rating and a $27.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Immunome has a consensus rating of “Buy” and an average price target of $29.80.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.